NCT07226843 2026-04-17
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Phase 1 Not yet recruiting
Clinical Trials
25 trialsNCT07528352 2026-04-17
REBEL
University of Utah
Phase 1 Not yet recruiting
NCT07476105 2026-04-15
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
Fondazione Italiana Linfomi - ETS
Phase NA Not yet recruiting
NCT07519772 2026-04-09
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Phase 1/2 Not yet recruiting
NCT07517705 2026-04-08
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase NA Not yet recruiting
NCT07507318 2026-04-02
DEL-MRD-CHID
Fudan University
Phase 2 Not yet recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07494565 2026-03-27
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07101328 2026-03-20
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07478848 2026-03-18
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT07463781 2026-03-13
NEURO_CAR-T
Fondazione Italiana Linfomi - ETS
Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07412405 2026-02-17
ACITAC-001
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Phase NA Not yet recruiting
NCT07398638 2026-02-10
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06594939 2026-02-04
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07365306 2026-01-26
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07310186 2025-12-30
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Peking Union Medical College Hospital
Not yet recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT07168291 2025-09-17
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1 Not yet recruiting
NCT07159906 2025-09-08
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2 Not yet recruiting
NCT07035379 2025-08-22
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2 Not yet recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT07024147 2025-06-17
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1 Not yet recruiting
NCT07012980 2025-06-10
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting